Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Kevin Hrusovsky, Nicolas Barthelemy

Premium

Quanterix has named Kevin Hrusovsky executive chairman of its board of directors.
Hrusovsky will replace Martin Madaus, who gave up his chairman seat to be chairman and CEO of Ortho-Clinical Diagnostics but who will remain on the Quanterix board.

Hrusovsky formerly was president of PerkinElmer Life Sciences & Technology. He was CEO of Caliper Life Sciences and joined PerkinElmer after that firm acquired Caliper in 2011 for $600 million. Hrusovsky also previously served as CEO of Zymark, and he was president of FMC Corporation's Pharmaceuticals and International Agricultural Products.


Repligen has appointed Nicolas Barthelemy to its board of directors. He spent the last nine years at Life Technologies, until Thermo Fisher Scientific acquired it, most recently serving as Life Tech's president of global commercial operations. Prior to joining Life Tech, he was vice president of manufacturing at Biogen and also the general manager for the company's manufacturing organization.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.